Edition:
India

Evotec SE (EVTG.DE)

EVTG.DE on Xetra

21.80EUR
18 Apr 2019
Change (% chg)

€-0.44 (-1.98%)
Prev Close
€22.24
Open
€22.08
Day's High
€22.37
Day's Low
€21.80
Volume
1,245,015
Avg. Vol
996,128
52-wk High
€25.83
52-wk Low
€12.06

Latest Key Developments (Source: Significant Developments)

Evotec, Almirall Enter Into Research Collaboration
Monday, 17 Sep 2018 

Sept 17 (Reuters) - Evotec AG ::EVOTEC AND ALMIRALL ENTER INTO RESEARCH COLLABORATION IN THE FIELD OF DERMATOLOGICAL DISEASES.WILL RECEIVE RESEARCH FUNDING AND MAY BE ELIGIBLE TO RECEIVE DISCOVERY, PRE-CLINICAL, CLINICAL AND SALES MILESTONE PAYMENTS AS WELL AS TIERED ROYALTIES.  Full Article

Evotec, Celgene Partner On Targeted Protein Degradation
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - Evotec AG ::DGAP-NEWS: EVOTEC AND CELGENE ENTER PARTNERSHIP IN THE FIELD OF TARGETED PROTEIN DEGRADATION.SAYS FINANCIALS INCLUDE UPFRONT PAYMENT AS WELL AS SIGNIFICANT POTENTIAL MILESTONE-BASED PAYMENTS AND ROYALTIE.  Full Article

Evotec To Integrate Sanofi's Infectious Diseases Unit
Monday, 18 Jun 2018 

June 18 (Reuters) - Evotec AG ::DGAP-NEWS: EVOTEC AND SANOFI SIGN DEFINITIVE AGREEMENT TO COMBAT INFECTIOUS DISEASES.100 EMPLOYEES WILL JOIN EVOTEC.SANOFI TO PROVIDE SIGNIFICANT SUPPORT TO EVOTEC INCLUDING A ONE-TIME, UPFRONT PAYMENT OF EUR 60 M.SANOFI WILL RETAIN CERTAIN OPTION RIGHTS ON DEVELOPMENT, MANUFACTURING AND COMMERCIALISATION OF ANTI-INFECTIVE PRODUCTS RESULTING FROM LICENSED ASSETS.TRANSACTION WILL RESULT IN INCREASED OPERATING INCOME AS WELL AS INCREASED RESEARCH AND DEVELOPMENT EXPENDITURE.TRANSACTION WILL BE SLIGHTLY ACCRETIVE TO EVOTEC'S EBITDA FOR NEXT FIVE YEARS.  Full Article

I'rom Group unit concludes iPS cell generation technology licensing agreement with Evotec International GmbH
Wednesday, 16 May 2018 

May 16 (Reuters) - I'rom Group Co Ltd <2372.T>:Says its unit ID Pharma Co., Ltd. concluded an iPS cell generation technology related licensing agreement with Germany company Evotec International GmbH .Says its unit will receive upfront payment and annual royalty from Evotec International GmbH .  Full Article

Evotec, Apeiron Biologics receive milestone payment from Sanofi
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Evotec Ag ::SAYS ‍EVOTEC AND APEIRON ACHIEVE FIRST MILESTONE IN IMMUNO-ONCOLOGY ALLIANCE WITH SANOFI​.SAYS ‍MILESTONE PAYMENT OF EUR 3 M WILL BE SPLIT EQUALLY BETWEEN TWO BIOTECH COMPANIES​.SAYS ‍SUCCESS PAYMENT WAS TRIGGERED WHEN PARTNERS SUCCESSFULLY ADVANCED AN UNDISCLOSED, NOVEL IMMUNO-ONCOLOGY SMALL MOLECULE INTO LATE-STAGE PRE-CLINICAL DEVELOPMENT​.SAYS ‍UNDER ALLIANCE, THREE COMPANIES WORK TOGETHER TO IDENTIFY SMALL MOLECULE LEADS AND TARGETS FOR NEXT-GENERATION THERAPIES IN IMMUNO-ONCOLOGY​.  Full Article

Evotec affirms guidance after 9-month core profit jump
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Evotec Ag :9M revenue rose 42 percent to 170.9 million eur.‍9M adjusted group EBITDA up 28% to eur 39.3 m (9m 2016: eur 30.6 m)​.Says ‍guidance 2017 confirmed​.  Full Article

Abivax and Evotec enter into strategic collaboration
Thursday, 7 Sep 2017 

Sept 7 (Reuters) - ABIVAX SA : :ABIVAX AND EVOTEC ENTER INTO STRATEGIC COLLABORATION TO DEVELOP NOVEL ANTIVIRAL AGENTS.  Full Article

Evotec completes acquisition of Aptuit
Wednesday, 16 Aug 2017 

Aug 16 (Reuters) - Evotec :Says completes acquisition of aptuit.  Full Article

Evotec confirms outlook after H1 core profit jump
Thursday, 10 Aug 2017 

Aug 10 (Reuters) - Evotec AG :H1 revenue rose 37 percent to 103.4 million eur.Group revenues: 37% increase to eur 103.4 m (h1 2016: eur 75.5 m);.Adjusted group EBITDA increased by 64%to eur 26.0 m (h1 2016: eur 15.8 m);.Strong strategic liquidity position of eur 187.0 m (prior to aptuit acquisition).research and development expenses slightly decreased by 5% to eur 8.5 m (h1 2016: eur 9.0 m).All elements of financial guidance comfortably confirmed.  Full Article

Evotec expands collaboration with Storm Therapeutics
Thursday, 27 Jul 2017 

July 27 (Reuters) - Evotec AG :Says expands collaboration with Storm Therapeutics on its RNA epigenetics platform.Says no financial details were disclosed.  Full Article